A biotech executive at a Los Angeles company turned out to be a fugitive wanted for more than 20 years.

When he was arrested, he was casually cruising at sea in a private yacht.
His name is Ronald Fischer. He was originally an anesthesiologist. In 2005, he went on trial for a first-degree sexual assault case, but fled during the proceedings.
Over the next 20 years, he used more than ten aliases, one of which was Richard Graydon.
He claimed that he held an MD and a PhD from Stanford University, had trained at Harvard University’s Massachusetts General Hospital, and had been involved at Merck and Johnson & Johnson in the development of seven approved drugs.
In 2017, he published a cancer genetic risk book under the name Graydon; in 2022, a U.S. listed company developing breast cancer drugs hired him as interim Chief Medical Officer. This year, in March, Los Angeles-based Immix Biopharma also hired him as Chief Medical Officer.
In July this year, U.S. marshals received a new lead about his whereabouts. Within less than 48 hours, investigators tracked a yacht registered under Graydon’s name.
On July 16, U.S. marshals and the Coast Guard intercepted the vessel offshore of New Jersey. Fischer was arrested on board without resistance.
At that time, he had been serving as the company’s Chief Medical Officer for less than four months.